State coverage
Maine Medicaid and GLP-1 coverage
Medicaid, for obesity: Other diagnoses only. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- Wegovy is covered for heart risk and a liver condition, Zepbound for sleep apnea. Weight loss stays excluded.
MaineCare's drug list carries a section headed WEIGHT LOSS, and it does not equivocate: weight-loss drugs are not covered, as permitted by federal Medicaid regulations and MaineCare policy. The list's own phrasing is "No longer covered" — Maine once paid for some of these and stopped.
Wegovy and Zepbound are not in that section. They sit instead under Cardiometabolic Health Agents and Obstructive Sleep Apnea, each covered for a reason that is not weight loss. Wegovy's route runs through reducing the risk of a major cardiac event — stroke, heart attack, symptomatic peripheral artery disease — in a patient who also has obesity or overweight, or through a liver condition called MASH. The drug list closes the loop with its own qualifier on the Wegovy entry: the patient's BMI must be over 27, and the drug must not be used for weight loss only.
Zepbound's route is narrower still and runs through sleep medicine rather than cardiology: a diagnosed case of moderate-to-severe obstructive sleep apnea, confirmed by a sleep study within the last three years, plus a documented history that CPAP either failed or could not be tolerated for at least 90 days.
The regulation behind all of this is old. MaineCare's benefits manual excludes anorexic and certain weight-loss drugs as a non-covered service — a provision the state's own hosted copy still stamps with a 2012 revision date, years before any of the current GLP-1s existed. Nothing in the current drug list contradicts it; the newer cardiometabolic and sleep-apnea pathways were built as exceptions that route around it, not as changes to it.
What we could verify for Maine
The current drug list carries a section headed WEIGHT LOSS and states: "No longer covered: Phentermine, Xenical, Didrex, and Weight loss drugs are not covered as permitted by Federal Medicaid regulations and Maine Medicaid (MaineCare) Policy."
MaineCare (Maine Department of Health and Human Services), MaineCare Preferred Drug List, effective July 2026 · source
The same drug list covers Wegovy for two reasons that are not weight loss. Under Cardiometabolic Health Agents, the criteria read: "Indication for use is Major Adverse Cardiac Event (MACE) Reduction: Patient has history of at least one of the following: Stroke, Myocardial Infarction, Symptomatic peripheral arterial disease," and separately, "Indication for use is Metabolic Dysfunction-Associated Steatohepatitis (MASH): Patient has metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis... Medication is being prescribed or in consultation with gastroenterologist, hepatologist, or endocrinologist." A closing note on the Wegovy entry reads: "Wegovy: Patient has BMI > 27 kg/m2, and is not being used for weight loss only."
MaineCare (Maine Department of Health and Human Services), MaineCare Preferred Drug List, effective July 2026 · source
The same list covers Zepbound only through sleep medicine: "Zepbound for adults with a BMI ≥ 30 mg/kg2 and diagnosis of moderate to severe OSA, confirmed by sleep study within the last 3 years documenting AHI ≥ 15, AND in which CPAP is ineffective (AHI > 5 during therapeutic section of sleep study) or patient is unable to tolerate CPAP for at least 90 days AND for whom lifestyle modifications have been attempted for at least 3 months with failure to achieve weight loss. Note: Not for patients with T1DM, T2DM."
MaineCare (Maine Department of Health and Human Services), MaineCare Preferred Drug List, effective July 2026 · source
The MaineCare Benefits Manual states the underlying exclusion by regulation: under Non-Covered Services, "MaineCare does not reimburse for the following drugs or products as drugs: A. Anorexic or certain weight loss drugs." The document is stamped "LAST UPDATED 7/1/12" on every page and is still the version hosted at maine.gov.
MaineCare Benefits Manual, 10-144 C.M.R. Chapter 101, Chapter II, Section 80 (Pharmacy Services), effective July 2012 · source
MaineCare's own administrative rule sets the filing window: "Unless otherwise specified in this Chapter, a request for an administrative hearing must be received within sixty (60) calendar days of the date of written notification to the member of the action the member wishes to appeal." A separate, shorter clock governs keeping your drug while you appeal: MaineCare services "currently being provided will not be terminated, reduced, or suspended until an administrative hearing decision is rendered provided that the member requests an administrative hearing before the date of action."
MaineCare Benefits Manual, 10-144 C.M.R. Chapter 101, Chapter I, Section 1, §1.24 · source
Maine is one of 33 states whose Medicaid gives the same answer: weight loss excluded; heart, liver or sleep apnea can qualify. Maine Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare Maine with the rest in the coverage matrix.
If you work for the State of Maine
State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: State of Maine Health Plan. Its pharmacy benefit runs through Capital Rx.
Weight loss GLP-1s covered only through Virta
Since July 1, 2026, your GLP-1 for weight loss stays covered only if you enroll in Virta Health and get the prescription from a Virta provider. After October 30, 2026, weight loss GLP-1s filled outside Virta aren't covered.
"Effective July 1, 2026: State of Maine Health Plan Members with GLP-1 prescriptions for weight loss are required to enroll in Virta Health and receive their GLP-1 prescription from a Virta provider to maintain coverage."
Maine Office of Employee Health, Wellness, & Workers' Compensation, Virta Health page, effective July 2026 · source
"After 10/30/2026, prescriptions for GLP-1 medications for weight loss filled outside of Virta will not be covered under the State of Maine Health Plan, and the member is responsible for the full out-of-pocket cost."
Maine Office of Employee Health, Wellness, & Workers' Compensation, Virta Health page, effective July 2026 · source
"This change applies only to GLP-1 medications prescribed for weight loss."
Maine Office of Employee Health, Wellness, & Workers' Compensation, Virta Health page, effective July 2026 · source
The State Employee Health Commission approved plan changes for July 1, 2026 that "implement Virta Responsible Prescribing and require program engagement to maintain GLP-1 prescription"; the minutes record "Motion approved."
State of Maine State Employee Health Commission, Minutes, March 19, 2026, effective March 2026 · source
Virta Responsible Prescribing "provides access to weight-loss medications, including GLP-1s, for Virta-enrolled members who have clinical indication for their use as part of their care plan."
State of Maine, 2026-2027 Benefits Guide, effective July 2026 · source
For diabetes, "The State of Maine covers diabetic medications at a $25 copay for 30-day supply at the Preferred Brand tier."
State of Maine, 2026-2027 Benefits Guide, effective July 2026 · source
If the appeal fails, or you cannot wait
Maine Medicaid excludes weight loss but can still approve these drugs for another approved use, set out in the facts above. If none of those applies to you, cash-pay telehealth is the fallback: you pay the whole cost yourself, with no Medicaid help.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
| Company | What we found on its own site |
|---|---|
| PartnerHumeCare+Check availability | A self-pay membership with no price shown before checkout, renewing automatically. The home page promises your money back if you don't lose 10 percent in six months; the terms limit that to 90 days, first-time users and no measurable loss. |
| PartnerEnhance MDCheck availability | Offers compounded semaglutide and tirzepatide with provider consultations and follow-up. Compounded drugs are not FDA-approved; ask which pharmacy will dispense your prescription and what continuing care includes. |
| PartnerCoreAge RxCheck availability | Compounded semaglutide advertised at $99 a month at every dose. The page our link opens has shown $149 instead, and a consultation fee can be added that may not be refundable. |
| PartnerOakCheck availability | One flat price at every dose, with shipping and supplies included free. |
| PartnerGala HealthCheck availability | One price at every dose. The advertised rate needs a yearly subscription. |
| PartnerDirect MedsCheck availability | One price at every dose from $147, with no monthly membership. The page states its discount two ways ($150 off in the banner, up to $200 off on the tiles), so check the total at checkout. |
All 21 companies, with what we found on each →
Prices in those notes were read from each company's own site in September 2026, October 2026 and August 2026, and they change often. Check the current number before you buy.
Where this comes from
- MaineCare (Maine Department of Health and Human Services), MaineCare Preferred Drug List, effective July 2026 — Open the document
- MaineCare Benefits Manual, 10-144 C.M.R. Chapter 101, Chapter II, Section 80 (Pharmacy Services), effective July 2012 — www.maine.gov/dhhs/sites/maine.gov.dhhs/files/documents/S80P_Pharmacy.pd
- MaineCare Benefits Manual, 10-144 C.M.R. Chapter 101, Chapter I, Section 1, §1.24 — www.maine.gov/sos/sites/maine.gov.sos/files/inline-files/c1s001.docx